Advanced search
Publication Cover
OncoTargets and Therapy Volume 6, 2013 - Issue
Submit an article Journal homepage
60
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Sequential treatment of tyrosine kinase inhibitors and chemotherapy for EGFR-mutated non-small cell lung cancer: a meta-analysis of Phase III trials

Yiliang Zhang1 Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, People’s Republic of China
,
Yihua Sun1 Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, People’s Republic of China
,
Lei Wang1 Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, People’s Republic of China
,
Ting Ye1 Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, People’s Republic of China
,
Yunjian Pan1 Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, People’s Republic of China
,
Haichuan Hu1 Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, People’s Republic of China
,
Yongfu Yu2 Department of Biostatistics, School of Public Health, Fudan University, People’s Republic of China
,
Naiqing Zhao2 Department of Biostatistics, School of Public Health, Fudan University, People’s Republic of China
,
Yanyan Song3 Department of Pharmacology and Biostatistics, Institute of Medical Science, Shanghai Jiaotong University School of Medicine, People’s Republic of China
,
David Garfield4 ProMed Cancer Centers, Shanghai, People’s Republic of China
&
Haiquan Chen1 Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 1771-1777 | Published online: 29 Nov 2013

References

  • KimESHirshVMokTGefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialLancet20083721809181819027483
  • ShepherdFARodriguesPJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med200535312313216014882
  • RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol20101323924622285168
  • MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med200936194795719692680
  • PaezJGJannePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience20043041497150015118125
  • MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med20103622380238820573926
  • ZhouCWuYLiuXOverall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC)J Clin Oncol201230Suppl Abstr 7520
  • GridelliCCiardielloFGalloCFirst-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trialJ Clin Oncol2011303002301122778317
  • ParmarMKTorriVStewartLExtracting summary statistics to perform meta-analyses of the published literature for survival endpointsStat Med199817281528349921604
  • TierneyJFStewartLAGhersiDBurdettSSydesMRPractical methods for incorporating summary time-to-event data into meta-analysisTrials200781617555582
  • Huedo-MedinaTBSanchez-MecaJMarin-MartinezFBotellaJAssessing heterogeneity in meta-analysis: Q statistic or I2 index?Psychol Methods20061119320616784338
  • AhmedISuttonAJRileyRDAssessment of publication bias, selection bias, and unavailable data in meta-analyses using individual participant data: a database surveyBMJ2012344d776222214758
  • StroupDFBerlinJAMortonSCMeta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) groupJAMA20002832008201210789670
  • FukuokaMWuYLThongprasertSBiomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)J Clin Oncol2011292866287421670455
  • InoueAKobayashiKMaemondoMUpdated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)Ann Oncol201324545922967997
  • MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol20101112112820022809
  • ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol20111273574221783417
  • HanJYParkKKimSWFirst-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lungJ Clin Oncol2012301122112822370314
  • CiardielloFTortoraGEGFR antagonists in cancer treatmentN Engl J Med20083581160117418337605

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.